Search Results for "therapeutic"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Neurofilament Light Chain as a Biomarker in Hereditary Transthyretin-Mediated Amyloidosis: 36-Month Data from the Patisiran Global Open-Label Extension

Final Results from a Phase 1/2, 48-Month, Open-Label Extension Study of Givosiran in Patients with Acute Intermittent Porphyria

Patient Experience with Acute Hepatic Porphyria Before and After Long-Term Givosiran Treatment: A Qualitative Interview Study

Kidney Function, Isolated Kidney Transplant, and Health-Related Quality-of-Life Outcomes in Primary Hyperoxaluria Type 1 Treated With Long-Term Lumasiran

Effectiveness of Patisiran Following Switch From Tafamidis for the Treatment of Hereditary Transthyretin Mediated (hATTR) Amyloidosis with Polyneuropathy

Patient Experience with Acute Hepatic Porphyria Before and After Long-Term Givosiran Treatment: A Qualitative Interview Study

Clinical outcomes and hemin use of patients with acute hepatic porphyria in the phase 3 ENVISION study who were not attack-free after 6 months of givosiran treatment

Design and Rationale of cAPPricorn-1, a Phase 2 Study of Mivelsiran in Patients With Cerebral Amyloid Angiopathy

Effect and Safety of Patisiran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy and Chronic Kidney Disease Results

Zilebesiran as Add-On Therapy in Patients With Hypertension Who Have Cardiovascular Disease or are at High Cardiovascular Risk: The ZENITH Trial Design

KARDIA-3 Study Design: Zilebesiran as Add-On Therapy in Patients with High Cardiovascular Risk and Hypertension Inadequately Controlled by Standard of Care Antihypertensives

Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B

Vutrisiran Reduces Days Lost to Death andor Hospitalization Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial

Maintenance or Improvement of Functional Capacity, Health Status, and Quality of Life with Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Data from the HELIOS-B Study

Likelihood of disease worsening in patients receiving tafamidis for ATTR amyloidosis with cardiomyopathy (ATTR-CM): A targeted literature review

Subgroup Results from KARDIA-2: Impact of Demographic and Baseline Disease Characteristics on Zilebesiran Response in Patients with Hypertension Uncontrolled by a Standard Oral Antihypertensive

Utility of Genetic Testing For Diagnosing hATTR Patients: Results from a European and Middle East Genetic Testing Program

Unmet Need in a Contemporary Cohort of Tafamidis-Treated Transthyretin Amyloid Cardiomyopathy Patients

NfL as a Potential Biomarker in hATTR Amyloidosis

This slide deck presents an overview of neurofilament light chain (NfL) and data evaluating its use as a biomarker in hATTR amyloidosis, including data from the APOLLO, Global OLE, and HELIOS-A studies.

Home Blood Pressure Reductions with Zilebesiran in Patients with Mild-To-Moderate Hypertension are Consistent with Ambulatory and Office Blood Pressure Reductions in the KARDIA-1 Study

Comparison of Patients With Primary Hyperoxaluria 1 and Late-Stage Chronic Kidney Disease From BONAPH1DE Registry and ILLUMINATE-C Lumasiran Trial

GRAPHICAL ABSTRACT: KARDIA-3 Study Design: Zilebesiran as Add-On Therapy in Patients with High Cardiovascular Risk and Hypertension Inadequately Controlled by Standard of Care Antihypertensives

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Zilebesiran as Add-On Therapy in Patients with Hypertension Inadequately Controlled with a Standard Antihypertensive Medication: Efficacy and Safety Results from the KARDIA-2 Study

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "therapeutic"

NfL as a Potential Biomarker in hATTR Amyloidosis This slide deck presents an overview of neurofilament light chain (NfL) and data evaluating its use as a biomarker in hATTR amyloidosis, including data from the APOLLO, Global OLE, and HELIOS-A studies.

NfL as a Potential Biomarker in hATTR Amyloidosis

This slide deck presents an overview of neurofilament light chain (NfL) and data evaluating its use as a biomarker in hATTR amyloidosis, including data from the APOLLO, Global OLE, and HELIOS-A studies.